AlphaFold predicted structure
HS2ST1 · Q7LGA3

Mean pLDDT
91.8/ 100
Very high
356 residues
Confidence breakdown
- Very high(≥ 90)76%
- Confident(70–90)17%
- Low(50–70)5%
- Very low(< 50)2%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
heparan sulfate 2-O-sulfotransferase 1
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
DDG2P
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalSkeletal dysplasia
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalCAKUT
BIALLELIC, autosomal or pseudoautosomalHoloprosencephaly
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalneurofacioskeletal syndrome with or without renal agenesis
Intellectual disability
multiple congenital anomalies/dysmorphic syndrome-intellectual disability
arthrogryposis
complex neurodevelopmental disorder
alcohol drinking
breast benign neoplasm
urolithiasis
appendicitis
hereditary disease
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Heparan sulfate 2-O-sulfotransferase 1
Catalyzes the transfer of a sulfo group from 3'-phospho-5'-adenylyl sulfate (PAPS) to the 2-OH position of iduronic acid (IdoA) or glucuronic acid (GlcA) within the heparan sulfate (HS) chain and participates in HS biosynthesis (By similarity). Required for metanephric development of kidney formation, suggesting that 2-O-sulfation within HS is essential for signaling between ureteric bud and metanephric mesenchyme (By similarity)
HS2ST1 · Q7LGA3

Mean pLDDT
91.8/ 100
Very high
356 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0